Summary
BeiGene Ltd. (ONC) reported on December 9, 2019, the presentation of clinical data for its BTK inhibitor, BRUKINSA™ (zanubrutinib), at the 61st American Society of Hematology (ASH) Annual Meeting. The data presented focused on trials involving patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), where BRUKINSA demonstrated consistent safety and high overall response rates (ORR).
Key Highlights
- 1Presentation of clinical data for BRUKINSA™ (zanubrutinib) at the 61st ASH Annual Meeting.
- 2BRUKINSA™ showed consistent safety and high overall response rates (ORR) in patients with CLL or SLL.
- 3Preliminary efficacy and good tolerability were observed for BRUKINSA™ in combination with tislelizumab in B-cell malignancies.
- 4The event date for this announcement was December 8, 2019.
- 5The press release detailing this data is filed as Exhibit 99.1.
Frequently Asked Questions
The data presented at the ASH Annual Meeting is significant as it showcases the clinical performance of BeiGene's BTK inhibitor, BRUKINSA™ (zanubrutinib), demonstrating its potential in treating specific blood cancers like CLL and SLL, as well as in combination therapies.
In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), BRUKINSA™ demonstrated consistent safety and a high overall response rate (ORR), suggesting positive efficacy.
The combination of BRUKINSA™ with BeiGene's investigational anti-PD-1 antibody tislelizumab showed preliminary efficacy and was generally well tolerated in patients with previously treated B-cell malignancies, indicating potential for a novel treatment approach.
The full text of the press release announcing the clinical data is available as Exhibit 99.1 to this Current Report on Form 8-K filed by BeiGene Ltd.